New Delhi [India], October 28: Sudarshan Pharma Industries shares surged nearly 7% on Wednesday, touching an intraday high of ₹37.30 against the previous closing price of ₹34.88, following the company’s announcement of a proposed strategic investment in US-based MedTherapy Biotechnology Inc.

The stock has a 52-week high of ₹42.79 and a low of ₹18.50, with the company’s market capitalisation standing at approximately ₹950 crore.

The company’s board recently approved the acquisition of a 9.50% equity stake in MedTherapy Biotechnology, a Delaware-incorporated biotechnology company specialising in cancer cell and gene therapies.

Founded in 2018, Boston-based MedTherapy focuses on CAR-T cell therapy development and manufacturing. The company operates a commercial-scale GMP manufacturing facility in New Delhi and a technology development centre in Boston.

According to Sudarshan Pharma, the proposed investment is expected to facilitate its entry into the US market while providing access to MedTherapy’s customer base, contracts and distribution network. The acquisition could also support diversification into new products and services.

The transaction consideration will be determined based on prevailing valuation norms and paid in US dollars. Completion is expected by March 31, 2027.

Meanwhile, Sudarshan Pharma reported a 45.05% year-on-year increase in consolidated net profit to ₹5.86 crore in Q1 FY27, while revenue rose 20.07% to ₹174.42 crore.

The company manufactures active pharmaceutical ingredients (APIs) and trades in chemicals and solvents, with manufacturing facilities in Maharashtra and Hyderabad.